Pharmacist Digest

The U.K. just cleared a drug to prevent breast cancer. U.S. women may not know it’s already an option

STAT

NOVEMBER 13, 2023

has approved a preventive drug for post-menopausal women at risk of developing breast cancer wasn’t a shock to breast medical oncologist Abenaa Brewster. But the fact that a patient in her breast cancer prevention clinic hadn’t ever heard of such a possibility before was. The news that the U.K.

Cancer disparities persisted even among clinical trial participants, study finds

STAT

OCTOBER 25, 2023

Participation in a clinical trial is often considered something of an equalizer in medicine. But a new study suggests that increasing trial diversity won’t be enough to eliminate health disparities. Read the rest…

Breast cancer is deadlier for Black women. A study of mammograms could help close the gap

STAT

OCTOBER 17, 2023

Are 3D mammograms better than standard 2D imaging for catching advanced cancers? A clinical trial is recruiting thousands of volunteers — including a large number of Black women who face disparities in breast cancer death rates — to try to find out. Read the rest…

Opinion: New federal guidance is hurting cancer patients, especially those in rural areas

STAT

MARCH 1, 2024

I recently started a patient with metastatic triple-positive breast cancer patient on a targeted therapy regimen consisting of capecitabine and neratinib, both oral chemotherapy pills that are dosed on a 21-day cycle. Read the rest…

Specialty Pharmacies

Specialty Pharmacies Chemotherapy

What could fix cancer clinical trials’ longstanding diversity problem?

STAT

SEPTEMBER 7, 2023

There’s a diversity problem in cancer clinical trials, and few know this better than Stephanie Walker. When she was diagnosed with stage 4 metastatic breast cancer, Walker said there was no one to help her figure out the system, not even a nurse or patient navigator.

STAT+: House bill aimed at Chinese biotechs is advancing

STAT

APRIL 29, 2024

Today, we learn there are some serious safety concerns around an experimental blood cancer drug from MorphoSys that has been the centerpiece of Novartis’ plan to acquire the company for $3 billion. Want to stay on top of the science and politics driving biotech today? Continue to STAT+ to read the full story…

Immunity

Immunity Immunization Vaccines

Scorpion Therapeutics announces first patient dosed in clinical trial for the treatment of breast cancer and solid tumors

Outsourcing Pharma

MAY 3, 2023

Scorpion Therapeutics, a clinical-stage oncology company, has announced that the first patient has been dosed in a phase 1/2 clinical trial of STX-478, its treatment for breast cancer and other solid tumors.

STAT+: Lilly turns to nonprofit, not the FDA, to resolve dispute with Novartis over a prescription drug ad

STAT

JANUARY 25, 2023

The dispute began when Eli Lilly challenged some of the information in an ad that Novartis had run for its Kisqali breast cancer treatment. Specifically, Lilly objected to language about the overall survival rate in Kisqali clinical trials that suggested the drug was superior to similar cancer medications.

STAT+: Gilead drug prolongs survival of women with common form of breast cancer

STAT

SEPTEMBER 8, 2022

Gilead Sciences said Wednesday that its cancer drug Trodelvy prolonged the survival of women with the most common form of breast cancer by just under 30% — a clinical trial result that could lead to a better treatment option for patients with advanced disease and strengthen the drug’s commercial outlook.

Chemotherapy

Enhertu shows positive results in DESTINY-Breast06 Phase III trial

Express Pharma

APRIL 29, 2024

A statistically significant and clinically meaningful improvement in PFS was also observed in the overall trial population (patients with HER2-low and HER2-ultralow [defined as IHC 0 with membrane staining; IHC >0<1+] metastatic breast cancer).

Chemotherapy

AstraZeneca’s Lynparza to dominate PARP inhibitors market with $4 bn in sales by 2027: GlobalData

Express Pharma

APRIL 25, 2024

In 2014, the FDA approved the first (adenosine diphosphate-ribose) polymerase (PARP) inhibitor AstraZeneca /Merck’s Lynparza (olaparib) for use in breast cancer gene (BRCA)-mutated metastatic ovarian cancer patients who have received three or more prior lines of chemotherapy.

Chemotherapy

STAT+: Hair loss is one of the most hated chemotherapy side effects. A new biotech hopes to prevent it

STAT

JANUARY 17, 2024

The chemotherapy Christine Ko was prescribed for her breast cancer is pretty much a guarantee for losing your hair. But as a dermatologist at Yale Cancer Center, Ko knew there simply weren’t any other options. Once developed, the antibody will also still need to make it through clinical trials.

Chemotherapy

Chemotherapy Drug Development

Enhertu approved in China for patients with HER2-low metastatic breast cancer

LifeProNow

JULY 14, 2023

The approval by China’s National Medical Products Administration (NMPA) is based on the results of the DESTINY-Breast04 Phase III trial , first presented at the American Society of Clinical Oncology 2022 Annual Meeting and published in The New England Journal of Medicine. Approximately half of all breast cancers are considered HER2-low.

Chemotherapy

Chemotherapy Hospitals

Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis for breast cancer

LifeProNow

MARCH 27, 2023

While most patients are diagnosed and treated early with the aim to cure breast cancer, the risk of cancer returning, often as metastatic disease, peaks within three years after diagnosis, but never goes away completely,” said Dennis J. President, Global Drug Development and Chief Medical Officer, Novartis.

Chemotherapy

Chemotherapy Labelling Drug Development

NICE recommends innovative breast cancer drug

European Pharmaceutical Review

JANUARY 19, 2024

The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending Pfizer’s TALZENNA ® (talazoparib) for HER2- negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations.

Chemotherapy

Chemotherapy Labelling Pharmaceutical Companies Pharmaceutical Companies

Scientists investigate if prostate drug could also treat breast cancer that’s spread to the bone

Express Pharma

AUGUST 25, 2023

When breast cancer cells spread to other parts of the body it is called secondary or metastatic breast cancer and although treatable cannot be cured Researchers at the University of Sheffield are testing new combinations of drugs to treat breast cancer that’s spread to the bone with the help of funding from Breast Cancer Now.

STAT+: Rise in cancer among younger people worries and puzzles doctors

STAT

JULY 24, 2023

Further testing over the next couple of weeks clarified the cause: Gosline had stage 4 colorectal cancer, which had spread to his liver. That’s “the very hard question that none of us really know the answer to,” said Timothy Rebbeck, professor of cancer prevention at the Harvard T.H. Chan School Of Public Health.

Medical Schools

Medical Schools Hospitals Chemotherapy Immunity

Google Cloud’s health strategy, NIH’s Covid data dilemma, & rumored telehealth mergers

STAT

NOVEMBER 29, 2022

Using Google’s AI Model — and its cloud infrastructure, which I’ll share more about later — could boost adoption of iCAD’s broader cancer detection services, an executive said in a press release. Read the rest…

Collaboration to develop novel AI-designed oncology therapy

European Pharmaceutical Review

JANUARY 5, 2024

This treatment has potential for hormone sensitive cancers such as breast cancer, and other oncology indications. First AI-generated small molecule drug enters Phase II trial Advancing an AI-designed breast cancer therapy Overexpression of KAT6A correlates with poor clinical outcomes in ER+/HER2- breast cancer.

For many older breast cancer patients, study finds radiation doesn’t affect survival

STAT

FEBRUARY 15, 2023

Radiation has long been a mainstay of breast cancer treatment, and following surgery up with the therapy can reduce the risk of recurrence. Now the results of a Phase 3 trial suggests that many older patients may not need radiation and can go without it after surgery without harming their overall survival.

DX-126262 by Hangzhou DAC Biotech for Breast Cancer: Likelihood of Approval

Pharmaceutical Technology

FEBRUARY 8, 2024

DX-126262 is under clinical development by Hangzhou DAC Biotech and currently in Phase I for Breast Cancer.

Combination treatment could minimise cancer relapse risk

European Pharmaceutical Review

MARCH 22, 2024

Research suggests that combining ribociclib with hormone therapy improved invasive-free survival in stage 2 or 3 HR-positive, HER2-negative early breast cancer. And that is huge for this the group of patients, who make up 70 percent to 75 percent of breast cancer cases.”

Health Canada gives approval to Enhertu for breast cancer treatment

Pharmaceutical Technology

JANUARY 13, 2023

Health Canada has granted approval to Enhertu (trastuzumab deruxtecan) to treat unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer. Enhertu’s safety profile was consistent with the previous clinical trials.

Adverse Reactions

Adverse Reactions Chemotherapy

CHMP meeting highlights: April 2024

European Pharmaceutical Review

APRIL 30, 2024

Recommendations for new cancer treatments The committee also adopted a positive opinion for Fruzaqla (fruquintinib) for previously treated metastatic colorectal cancer in adults. Generic medicine Eribulin Baxter (eribulin) was also granted a positive opinion by the committee, to treat breast cancer and liposarcoma.

MHRA authorisation is first endocrine therapy innovation in decades

European Pharmaceutical Review

JANUARY 3, 2024

Korserdu ® (elacestrant) is the first treatment indicated for ER+, HER2- advanced or metastatic breast cancer tumours with ESR1 mutations. Data supporting MHRA’s authorisation of Korserdu (elacestrant) Data from the Phase III EMERALD trial was published in the ASCO Journal of Clinical Oncology. months versus 1.9 months versus 1.9

B-Vaxx by Imugene for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval

Pharmaceutical Technology

APRIL 17, 2024

B-Vaxx is under clinical development by Imugene and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).

Immutep reveals initiation of pivotal Efti study

Pharma Times

MARCH 14, 2023

The clinical trial also involves paclitaxel in the treatment of metastatic breast cancer

Successful Clinical Outcomes With Treatment in Advanced-Stage Breast Cancer

Pharmacy Times

JUNE 30, 2022

Moore, PharmD, BCOP, CPP, and Susan Faye Dent, MD, FRCPC, FICQS, emphasize the critical role of the pharmacist in achieving clinical endpoints in advanced-stage breast cancer.

Sathgen Therapeutics announces completion of first cohort in phase 1 clinical trial with anti-cancer drug

Express Pharma

JULY 17, 2023

Clinexel Life Sciences, a leading clinical research organisation, is supporting and managing the clinical development programme for global approvals. Sathgen aims to develop MSP008-22 for difficult-to-treat cancers, starting with triple negative breast cancer (TNBC) and prostate cancer as proof-of-principle.

Chemotherapy

Zum Heilen announces patent for cardamom-based nutraceutical Recovereez

Express Pharma

SEPTEMBER 17, 2023

Reportedly, a comprehensive clinical study conducted by Dr Varkey and his team has revealed that cardamom has profound anti-inflammatory activities, solidifying its potential as a valuable addition in treatment of various conditions ranging from respiratory health to cancer.

Will ESR1-mutated breast cancer treatment gain approval?

European Pharmaceutical Review

JULY 24, 2023

A novel breast cancer treatment The anti-cancer therapeutic is indicated for postmenopausal women, and adult men, with these clinical biomarkers. The post Will ESR1-mutated breast cancer treatment gain approval? ESR1 mutations are acquired mutations that develop due to endocrine therapy exposure.

First patient dosed in Scancell’s clinical trial for multiple cancers

Pharma Times

JUNE 13, 2022

First-in-human clinical trial in patients with triple negative breast cancer, ovarian cancer, head and neck cancer and renal cancer

Bayer extends elinzanetant trials to include breast cancer

pharmaphorum

OCTOBER 17, 2022

Bayer has added another clinical trial to its extensive phase 3 programme for oral neurokinin antagonist elinzanetant, hoping to show that it can treat vasomotor symptoms (VMS) in breast cancer patients. There are around 2.3

Antibody-drug conjugates: paving the future of oncology clinical development

European Pharmaceutical Review

OCTOBER 26, 2023

In August 2023, Biswajit Podder, PhD, Oncology and Hematology Analyst at GlobalData shared that HER2-positive breast cancer “seems to be a major focus” in ADC drug development. Clinically meaningful PFS benefit was seen in patients with non-squamous tumours. Can you summarise the key new data from the TROPION-programme?

Chemotherapy

Chemotherapy Drug Development

AC-0682 by Accutar Biotechnology for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

Pharmaceutical Technology

FEBRUARY 19, 2024

AC-0682 is under clinical development by Accutar Biotechnology and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer).

Big day for AZ, Daiichi as Enhertu aces HER2-low breast cancer trial

pharmaphorum

FEBRUARY 21, 2022

Already making inroads as a treatment for HER2-positive breast cancer, AstraZeneca and Daiichi Sankyo’s Enhertu has now shown efficacy in tumours that express lower levels of HER2 – potentially making it an option for a much broader group of patients.

Chemotherapy

Chemotherapy Labelling

EMA validates Daiichi Sankyo-AstraZeneca’s cancer therapy applications

Pharmaceutical Business Review

MARCH 4, 2024

One application pertains to the treatment of adults with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who are in need of systemic therapy after previous treatment. The data underpinning these applications come from the TROPION-Lung01 and TROPION-Breast01 Phase III clinical trials.

Labelling

Enfortumab vedotin by Astellas Pharma for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

Pharmaceutical Technology

FEBRUARY 7, 2024

Enfortumab vedotin is under clinical development by Astellas Pharma and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer).

Trastuzumab biosimilar by Qilu Pharmaceutical for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval

Pharmaceutical Technology

FEBRUARY 7, 2024

Trastuzumab biosimilar is under clinical development by Qilu Pharmaceutical and currently in Phase III for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).

Biosimilars

Triple Negative Breast Cancer Drug Development Digital Summit

pharmaphorum

FEBRUARY 10, 2021

This is the primary industry platform specifically dedicated to providing you insight into the latest developments of safe and efficacious blockbuster therapies to treat triple negative breast cancer. The post Triple Negative Breast Cancer Drug Development Digital Summit appeared first on.

Drug Development

Drug Development Immunity Immunization Vaccines

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Breast Cancer: Likelihood of Approval

Pharmaceutical Technology

APRIL 19, 2024

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Breast Cancer.

AstraZeneca-Daiichi Sankyo’s Enhertu gets US FDA approval for breast cancer

Pharmaceutical Technology

AUGUST 8, 2022

AstraZeneca and Daiichi Sankyo ’s Enhertu (trastuzumab deruxtecan) has received expanded approval from the US Food and Drug Administration (FDA) to treat adults with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer. In these subjects, the median progression-free survival (PFS) following Enhertu treatment was 9.9

Chemotherapy

Chemotherapy Labelling

SABCS: Pharmas show their working in HR+/HER2- breast cancer

pharmaphorum

DECEMBER 12, 2022

The San Antonio Breast Cancer Symposium (SABCS) has highlighted some of the most promising clinical research being undertaken by drugmakers in the category, with AstraZeneca leading the charge with a trio of major trial readouts. after four years’ follow-up, an improvement on the 2.8% seen at two years.

Chemotherapy

Evaluating the Impact of Metastatic Breast Cancer on Patients

Pharmacy Times

MAY 7, 2024

An expert panel discusses the clinical and economic impact of metastatic breast cancer (mBC) on patients, the prognosis for those with mBC, the three FDA-approved CDK4/6 inhibitors for HR+/HER2- mBC, and the importance of overall survival as a clinical trial endpoint and its relevance to clinical practice.

The U.K. just cleared a drug to prevent breast cancer. U.S. women may not know it’s already an option

Cancer disparities persisted even among clinical trial participants, study finds

Trending Sources

Breast cancer is deadlier for Black women. A study of mammograms could help close the gap

Opinion: New federal guidance is hurting cancer patients, especially those in rural areas

What could fix cancer clinical trials’ longstanding diversity problem?

STAT+: House bill aimed at Chinese biotechs is advancing

Scorpion Therapeutics announces first patient dosed in clinical trial for the treatment of breast cancer and solid tumors

STAT+: Lilly turns to nonprofit, not the FDA, to resolve dispute with Novartis over a prescription drug ad

STAT+: Gilead drug prolongs survival of women with common form of breast cancer

Enhertu shows positive results in DESTINY-Breast06 Phase III trial

AstraZeneca’s Lynparza to dominate PARP inhibitors market with $4 bn in sales by 2027: GlobalData

STAT+: Hair loss is one of the most hated chemotherapy side effects. A new biotech hopes to prevent it

Enhertu approved in China for patients with HER2-low metastatic breast cancer

Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis for breast cancer

NICE recommends innovative breast cancer drug

Scientists investigate if prostate drug could also treat breast cancer that’s spread to the bone

STAT+: Rise in cancer among younger people worries and puzzles doctors

Google Cloud’s health strategy, NIH’s Covid data dilemma, & rumored telehealth mergers

Collaboration to develop novel AI-designed oncology therapy

For many older breast cancer patients, study finds radiation doesn’t affect survival

DX-126262 by Hangzhou DAC Biotech for Breast Cancer: Likelihood of Approval

Combination treatment could minimise cancer relapse risk

Health Canada gives approval to Enhertu for breast cancer treatment

CHMP meeting highlights: April 2024

MHRA authorisation is first endocrine therapy innovation in decades

B-Vaxx by Imugene for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval

Immutep reveals initiation of pivotal Efti study

Successful Clinical Outcomes With Treatment in Advanced-Stage Breast Cancer

Sathgen Therapeutics announces completion of first cohort in phase 1 clinical trial with anti-cancer drug

Zum Heilen announces patent for cardamom-based nutraceutical Recovereez

Will ESR1-mutated breast cancer treatment gain approval?

First patient dosed in Scancell’s clinical trial for multiple cancers

Bayer extends elinzanetant trials to include breast cancer

Antibody-drug conjugates: paving the future of oncology clinical development

AC-0682 by Accutar Biotechnology for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

Big day for AZ, Daiichi as Enhertu aces HER2-low breast cancer trial

EMA validates Daiichi Sankyo-AstraZeneca’s cancer therapy applications

Enfortumab vedotin by Astellas Pharma for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

Trastuzumab biosimilar by Qilu Pharmaceutical for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval

Triple Negative Breast Cancer Drug Development Digital Summit

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Breast Cancer: Likelihood of Approval

AstraZeneca-Daiichi Sankyo’s Enhertu gets US FDA approval for breast cancer

SABCS: Pharmas show their working in HR+/HER2- breast cancer

Evaluating the Impact of Metastatic Breast Cancer on Patients

Stay Connected